REG - Biodexa Pharma - Exercise of Warrants and Issue of Equity
28/03/2023 18:30
For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20230328:nRSb5277Ua&default-theme=true
RNS Number : 5277U Biodexa Pharmaceuticals PLC 28 March 2023
28 March 2023
Biodexa Pharmaceuticals PLC
("Biodexa" or the "Company")
Exercise of Warrants and Issue of Equity
Total Voting Rights
Biodexa Pharmaceuticals PLC (AIM: BDRX; Nasdaq: BDRX), a drug delivery
technology company focused on improving the bio-delivery and biodistribution
of medicines, announces that it has today issued to various US investors
7,473,095 new ordinary shares of £0.02 each in the Company ("New Ordinary
Shares"), pursuant to the exercise notices in respect of 848,068 A Warrants
and 646,551 B Warrants received yesterday. All such warrants were exercised on
a cashless basis and further details are set out in the Company's circular
dated 7 March 2023.
Admission and total voting rights
Application has been made to the London Stock Exchange plc for the admission
to trading on AIM of the New Ordinary Shares, which is expected to become
effective and dealings commence at 8.00 a.m. on or around 3 April 2023
("Admission"). The New Ordinary Shares will rank pari passu with the existing
ordinary shares.
The Company's enlarged issued share capital on Admission will comprise
16,140,432 ordinary shares, each with voting rights. The Company does not hold
any shares in treasury. This figure of 16,140,432 ordinary shares may be used
by shareholders in the Company as the denominator for the calculations by
which they will determine if they are required to notify their interest in, or
a change in their interest in, the share capital of the Company under the
FCA's Disclosure Guidance and Transparency Rules.
Unless otherwise defined, capitalised terms used in this announcement have the
same meanings as ascribed to them in the Company's circulated dated 7 March
2023.
This announcement contains inside information for the purposes of Article 7 of
EU Regulation 596/2014, as it forms part of UK domestic law by virtue of the
European Union (Withdrawal) Act 2018, as amended.
For more information, please contact:
Biodexa Pharmaceuticals PLC
Stephen Stamp, CEO, CFO
Tel: +44 (0)29 2048 0180
www.midatechpharma.com (http://www.midatechpharma.com/)
Strand Hanson Limited (Nominated Adviser and Broker)
James Dance / Matthew Chandler / Rob Patrick
Tel: +44 (0)20 7409 3494
IFC Advisory Limited (Financial PR and UK Investor Relations)
Tim Metcalfe / Graham Herring
Tel: +44 (0)20 3934 6630
Email: midatech@investor-focus.co.uk
Edison Group (US Investor Relations)
Alyssa Factor
Tel: +1 (860) 573 9637
Email: afactor@edisongroup.com
About Biodexa Pharmaceuticals PLC
Biodexa Pharmaceuticals PLC (dual listed on AIM: BDRX; and NASDAQ: BDRX) is a
drug delivery technology company focused on improving the bio-delivery and
bio-distribution of medicines. The Company combines approved and development
medications with its proprietary and innovative drug delivery technologies to
provide compelling products that have the potential to powerfully impact the
lives of patients.
The Company has developed three in-house technology platforms, each with its
own unique mechanism to improve delivery of medications to sites of disease.
All of the Company's technologies have successfully entered human use in the
clinic, providing important validation of the potential for each platform:
· Q-Sphera™ platform: a disruptive micro-technology used for
sustained release to prolong and control the release of therapeutics over an
extended period of time (from weeks to months).
· MidaSolve™ platform: an innovative nanotechnology used to dissolve
insoluble drugs so that they can be administered in liquid form directly and
locally into tumours.
· MidaCore™ platform: a leading-edge nanotechnology used for
targeting medications to sites of disease.
The platform nature of the technologies offers the potential to develop
multiple drug assets rather than being reliant on a limited number of
programmes. Biodexa's technologies are supported by 36 patent families
including 120 granted patents and an additional 70 patent applications.
Biodexa's headquarters and R&D facility is in Cardiff, UK.
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
or visit
www.rns.com (http://www.rns.com/)
.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
. END IOEFLFFRVVITFIV